Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease
Posted inNeurology news Psychiatry

Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease

Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, suggesting that tau staging is essential for identifying metabolic and psychiatric vulnerability in the AD spectrum.
Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease
Posted inNeurology news Radiology

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive decline and offer a more precise framework for clinical intervention in Alzheimer's disease.
Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline
Posted inNeurology news Public Health

Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline

Emerging evidence confirms that air pollution, particularly PM2.5 and NO2, is directly associated with Alzheimer’s neuropathology, structural brain changes, and cognitive decline. New research highlights that these effects are partially mediated by pulmonary function and manifest as increased amyloid-related pathology at autopsy.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience
Posted inNeurology news Pathology & Lab Medicine

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.
Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir
Posted inNeurology news Psychiatry

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive decline compared to placebo over 78 weeks, cautioning against off-label use.
Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Posted inAllergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.
Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study
Posted inNeurology news

Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study

Autopsy of aducanumab-treated Alzheimer’s cases shows preferential clearance of superficial layer I amyloid, PET Centiloid reductions, and ARIA-associated microvascular pathology, implicating perivascular amyloid removal and vessel injury as mechanisms that inform monitoring and therapy design.
Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals
Posted inNeurology news

Two-Year 40 Hz Audiovisual Stimulation in Mild Alzheimer’s: Safety, EEG Entrainment, and Early Biomarker Signals

An open-label two-year extension in five patients with mild Alzheimer's disease found daily 1‑hour 40 Hz audiovisual stimulation to be safe, produced sustained EEG gamma entrainment in late‑onset cases, and was associated with smaller cognitive decline and reductions in plasma pTau217 in two participants, warranting controlled trials.